Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1
about
Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine developmentHIV-1 antibodies from infection and vaccination: insights for guiding vaccine designCatching HIV 'in the act' with 3D electron microscopyAntigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cellsStructure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine designCrystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1Structural Analysis of Human and Macaque mAbs 2909 and 2.5B: Implications for the Configuration of the Quaternary Neutralizing Epitope of HIV-1 gp120Cross-neutralization of influenza A viruses mediated by a single antibody loopA Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan ShieldStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeBroadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding GlycansReshaping Antibody DiversityFunctional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIVNeutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptorRecent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal AntibodiesAntibody potency relates to the ability to recognize the closed, pre-fusion form of HIV EnvHuman antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesStructure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopyHumanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Survivors Remorse: antibody-mediated protection against HIV-1.Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies.Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies.Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.Identification of nitrated immunoglobulin variable regions in the HIV-infected human brain: implications in HIV infection and immune response."Rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies.Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection.Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodiesLlama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C.Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes.Neutralisation of HIV-1 cell-cell spread by human and llama antibodies.Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.Accessing of recombinant human monoclonal antibodies from patient libraries by eukaryotic ribosome display.Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeastNeutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.
P2860
Q21558777-CC231BB6-19CF-4353-BFF7-0E50920B9192Q27022055-37EE1C95-EFFD-4C9A-836D-09DE96A3A114Q27026806-F3E62B00-9493-4125-A652-93E6DD6B7144Q27320687-E56F7A7B-4197-4C32-8192-7968979598F6Q27644478-C631BC9D-CCB3-4196-B6EA-66CACC53632BQ27644634-454A523A-0F30-44AF-8384-0410853112A6Q27662167-6C3B8F01-E9A0-4BF9-A936-3B5322660DB5Q27666407-44C0494E-3986-4DF4-94B1-14B51B5E1160Q27667819-DD3FA482-2AF7-4233-89C4-ABCCE23CDC14Q27673206-30D74307-9BB9-4E86-B3FC-B02DDC5929DEQ27675032-FEB3F246-0C93-4E7E-97E0-EEC67EEB95C3Q27675260-CEE8AE89-6271-4E1F-9DF6-BF178A9DA0E6Q27678062-C6C8DB6D-F17D-4BE2-A64D-8A39A1E80095Q27678538-CA8F4B7C-591A-47BA-B5E1-842E6954D86DQ27681527-6CF5910B-E8B3-4320-974F-B076223552DBQ27684529-FA10A6A6-A9C2-4ADD-AC15-63C5070373F8Q28068946-ECF50BD5-34E2-429F-A939-6A4E20F31423Q28256508-7228155A-08A5-4E9E-84C4-2DA41F101CA9Q28602877-D3D5852E-E144-425E-9E86-E0BCD8C754BDQ28654490-2ACD27F6-C34B-47BC-93CF-14EF4BFD26A0Q30234773-26348DA3-6904-48CF-91D1-99FD3F7EB27CQ30238730-04CEC86A-B0FF-4B50-A9A8-50AC386DBFF5Q30352300-B0E9E4E7-825B-42F6-8FAD-1A00DCB09902Q30353580-9A09D340-04AE-4152-AF07-4C4EAAE97DC6Q30425594-C3E7AEA4-5058-436C-ABF9-A2FC94F9135CQ30657338-B5E46124-7D0F-493E-87C1-1C9B74001DA7Q31132248-43D48F63-2377-453C-85A3-D485B3E7DCACQ33870575-95147C97-21C6-4FC9-A070-3CD3E398C4BAQ33941047-5DC56794-2F5B-4570-ACFA-31BE6637593DQ34022578-94C2BDC4-ADDE-45B4-8E38-456454B2107BQ34034659-7E2C5099-B85C-474F-97C4-C251E702093EQ34164923-F82A56AC-FAB0-4A9C-9154-2E523B094EBFQ34206171-9D173C01-276D-41EA-BA50-4BE8CF93DF02Q34270980-184003E4-ED4D-4590-A136-F77BC19310C9Q34304203-27204B99-1955-4E21-BB1C-33E8366A1424Q34350894-D3BD2C4B-0B25-49B3-8EB9-478A11206F10Q34376844-7E7022D1-E32A-4A05-BE18-8E089D9A8AF3Q34480254-A7E4929E-330B-47AA-87C3-3CA36CC5BCB1Q34550046-806B4449-E375-459E-924E-271F95619869Q34555891-0FEF5D6A-0844-4834-9DBC-F767A8965F93
P2860
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Structure and function of broa ...... potent neutralization of HIV-1
@ast
Structure and function of broa ...... potent neutralization of HIV-1
@en
Structure and function of broa ...... potent neutralization of HIV-1
@nl
type
label
Structure and function of broa ...... potent neutralization of HIV-1
@ast
Structure and function of broa ...... potent neutralization of HIV-1
@en
Structure and function of broa ...... potent neutralization of HIV-1
@nl
prefLabel
Structure and function of broa ...... potent neutralization of HIV-1
@ast
Structure and function of broa ...... potent neutralization of HIV-1
@en
Structure and function of broa ...... potent neutralization of HIV-1
@nl
P2093
P2860
P3181
P356
P1476
Structure and function of broa ...... potent neutralization of HIV-1
@en
P2093
Dennis R Burton
Laura M Walker
Robert Pejchal
Robyn L Stanfield
Sanjay K Phogat
Wayne C Koff
P2860
P304
P3181
P356
10.1073/PNAS.1004600107
P407
P577
2010-06-22T00:00:00Z